ImmuPharma Raises £125,000, Angle Directors Depart Amidst Disappointing Interims

ImmuPharma raised £125,000 from warrant exercises and filed a new patent application for P140, increasing the share price by 174%. 80 Mile agreed to a deal with Nasdaq shell Pelican Acquisition Corporation valuing a 70% stake in the Jameson liquid hydrocarbon project at $215m. Angle directors stepped down from the board following disappointing interims, and the share price dropped 53.3%. Active Energy Group raised £2.5m in an oversubscribed placing, but the share price dipped 37.5%. Finseta's interim figures showed revenues up 16% but gross margins declined, and the share price fell due to Shore's downgrade.

In the latest developments, ImmuPharma has experienced significant market activity. The company raised £125,000 from warrant exercises and filed a new patent application for P140, which resulted in a substantial increase in its share price by 174% 80 Mile shares surge on multi-million valuation of Greenland prospect^[1]. Meanwhile, 80 Mile PLC has secured a notable deal with Nasdaq shell Pelican Acquisition Corporation, valuing a 70% stake in the Jameson liquid hydrocarbon project at $215 million Angle PLC Announces Interim Results^[2]. This transaction has been positively received in the market, with 80 Mile's shares surging by 90% to 0.61 pence Angle PLC Announces Interim Results^[2].

On the other hand, Angle plc has faced challenges with its interim results. The company reported a loss of £9.3 million for the six months ended 30 June 2025, a significant increase from the previous year's loss of £7.7 million . The share price of Angle plc dropped by 53.3% following the disappointing interim results, reflecting investor concerns over the company's financial performance .

Active Energy Group also experienced market fluctuations. The company raised £2.5 million in an oversubscribed placing, but the share price dipped by 37.5% . This indicates that while the company successfully raised funds, the market reaction to the placing was negative, possibly due to broader market sentiment or specific concerns about the company's prospects.

Finseta's interim figures showed mixed results. The company reported revenues up by 16%, but gross margins declined, leading to a fall in the share price despite the positive revenue growth . The market reaction to Finseta's interim results was likely influenced by the downgrade from Shore, which may have negatively impacted investor confidence in the company's financial outlook.

Overall, these market developments highlight the varying fortunes of different companies, with some experiencing significant share price increases and others facing challenges that have led to share price declines. Investors should continue to monitor these companies closely for further updates and developments.